Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Conventional intestinal manometry is the current gold standard for the evaluation of intestinal motility, and identifies patterns of intestinal dysmotility. However intestinal manometry involves intestinal intubation with consequent discomfort for the patients, and requires considerable technical expertise and knowledge for interpretation of the data. Hence, to date this method has limited indications and is restricted to very few referral centers around the world.
A novel method for evaluation of intestinal motility has been developed based on endoluminal image analysis using the endoscopic PillCam capsule, In contrast to manometry, this technique is minimally invasive, the technical aspects are simple, and the analysis is fully automated by a computer program.
The technique has been validated in a group of patients with intestinal dysmotility and healthy subjects, and has demonstrated over 90% sensitivity and specificity.
This technique needs now to be validated in a large multinational population, to further develop a robust discrimination algorithm for widespread diagnostic application. Furthermore, whereas manometry only recognizes neuropathic, myopathic and obstructive motor patterns, endoluminal image analysis may identify different categories of patients depending on the clinical presentation and the etiologic factors involved.
This study is designed to provide evidence that the algorithm, using images created by PillCam SB2 capsules, is at least as good as small bowel manometry in diagnosing severe dysmotility.
Conventional intestinal manometry is the current gold standard for the evaluation of intestinal motility1,2,3,11, and identifies patterns of intestinal dysmotility4,8,9. However intestinal manometry involves intestinal intubation with consequent discomfort for the patients. Furthermore, it requires considerable technical expertise and knowledge for interpretation of the data. Hence, to date this method has limited indications and is restricted to very few referral centers around the world6,7,10,13.
Vall d'Hebron Hospital, in collaboration with CVC (Barcelona, Spain) have recently developed a minimally invasive method for evaluation of intestinal motility based on endoluminal image analysis using the endoscopic PillCam capsule. In contrast to manometry, this technique is minimally invasive, the technical aspects are simple, and the analysis is performed fully automated by a computer program. Both the technical procedure of the test and the endoluminal image analysis program has been developed by a multidisciplinary medical-engineering team in the Autonomous University of Barcelona over the past 5 years. The technique has been validated in a group of patients with intestinal dysmotility and healthy subjects, and has demonstrated over 90% sensitivity and specificity.
In brief, the technique works as follows. In each study a series of features are analyzed: contractile patterns (contractions evaluated as a diaphragmatic occlusion of the lumen and by the presence of a radial wrinkle pattern), non contractile patterns (wall and tunnel patterns), luminal content (turbid pattern), endoluminal motion, and capsule displacement.
The program is based on an automated learning method (machine learning technique). Data from patients and healthy subjects are used as a training set. Based on these data, the program develops the function that best discriminates both groups. The performance of the system has been validated using the leave-one-out method that uses all but one as training set and evaluates the left-out example.
This technique needs now to be validated in a large multinational population. Using this expanded pool of studies as a learning set, a robust discrimination algorithm will be developed, that can be made available for widespread diagnostic application. Furthermore, whereas manometry only recognizes neuropathic, myopathic5,12 and obstructive motor patterns, endoluminal image analysis may identify different categories of patients depending on the clinical presentation and the etiologic factors involved.
This study is designed to provide evidence that the algorithm, using images created by PillCam SB2 capsules, is at least as good as small bowel manometry in diagnosing severe dysmotility.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | Active Comparator | Patients previously indicated for manometry |
|
| Healthy volunteers | Active Comparator | Healthy volunteers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PillCam SB2 | Device | The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body. |
| Measure | Description | Time Frame |
|---|---|---|
| To Evaluate Accuracy of Endoluminal Image Analysis by Capsule Endoscopy in Detecting Severe Dysmotility | Patients were indicated for small bowel manometry based on one or both of the following symptoms:
| Up to 7 months |
| Measure | Description | Time Frame |
|---|---|---|
| To Assess Correlation Between Patient Clinical Symptoms and CE-EIA | The study was terminated without achieving the needed sample size due to very low recruitment rate. Therefore, no statistical analysis has been performed to achieve the secondary outcome. | Up to 7 months |
Not provided
Inclusion criteria - Patients
Patient's age is 16-80 years, inclusive.
One of the following SB manometry procedures:
Patient was indicated for small bowel manometry based on one or both of the following symptoms:
Patients may have any of the following:
Patients will be tested during period of (non-acute) remission. - Chronic severe GI symptoms with inability to maintain normal body weight: abdominal symptoms (such as nausea, abdominal distension, discomfort or pain) produce inability to maintain a normal body weight as defined by unintentional weight loss of at least 10% of original body weight before onset of symptoms or a BMI < 18.5, while on a normal diet (without oral dietary supplements, enteral or parenteral feeding).
These should be chronic symptoms lasting at least 6 months.
- Patient or legal guardian agrees to sign consent form
Exclusion criteria - Patients
Inclusion criteria - Healthy Volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fernando Azpiroz, Prof. | Universitat Autonoma de Barcelona | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Gastroenterology and Hepatology Mayo Clinic | Scottsdale | Arizona | 85259 | United States | ||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patients | Patients previously indicated for manometry |
| FG001 | Healthy Volunteers | Healthy volunteers |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase I - Development Phase |
| |||||||||||||
| Phase II - Validation Phase |
|
no analysis has been performd since study was premature terminated
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Patients | Patients previously indicated for manometry PillCam SB2: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | To Evaluate Accuracy of Endoluminal Image Analysis by Capsule Endoscopy in Detecting Severe Dysmotility | Patients were indicated for small bowel manometry based on one or both of the following symptoms:
| Total of 143 cases were enrolled. Phase 1- total of 106 cases (52 healthy volunteers, 54 patients) provided sensitivity and specificity results to train an algorithm. Phase 2- total of 37 cases (16 healthy volunteers, 21 patients) was intended to validate the sensitivity/specificity but study was terminated and the 37 cases were not analyzed. | Posted | Number | percentage | Up to 7 months |
|
AE information was collected as occurs from screening visit through follow up phone call which could occur over up to 7 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patients | Patients previously indicated for manometry Two Moderate adverse events not related to studies procedure were reported within this study: abdominal pain and nausea. In one case (i.e., abdominal pain) emergency visit occurred and the adverse events was resolved within four days. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | Non-systematic Assessment |
This study terminated early due to slow recruitment. Phase 1 of the study enrolled but was intended to train an algorithm only.The validation phase 2 which supported objectives was not completed and the study objectives could not be evaluated.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| director of clinical affairs | Given Imaging | +972-4-9097774 | Hila.debby@givenimaging.com |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mayo Clinic, |
| Rochester |
| Minnesota |
| 55905 |
| United States |
| Center for GI Research, KU Leuven, | Leuven | 3000 | Belgium |
| Internal Medicine & Gastroenterology, University of Bologna, | Bologna | I-40138 | Italy |
| Autonomous University of Barcelona | Barcelona | 08035 | Spain |
| Departement of Internal Medicine, Sahlgrenska Universitetss | Gothenburg | 41345 | Sweden |
| NOT COMPLETED |
|
| BG001 |
| Healthy Volunteers |
Healthy volunteers PillCam SB2: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Age, Categorical | Count of Participants | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Patients | Patients previously indicated for manometry PillCam SB2: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body. |
|
|
| Secondary | To Assess Correlation Between Patient Clinical Symptoms and CE-EIA | The study was terminated without achieving the needed sample size due to very low recruitment rate. Therefore, no statistical analysis has been performed to achieve the secondary outcome. | The 2ndary outcome was to be calculated from subjects in Phase 2 (i.e. the validation phase) of the study but the study was terminated and the 37 participants in phase 2 were not analyzed | Posted | Up to 7 months |
|
|
| 0 |
| 75 |
| 0 |
| 75 |
| 2 |
| 75 |
| EG001 | Healthy Volunteers | Healthy volunteers PillCam SB2: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body. | 0 | 68 | 0 | 68 | 0 | 68 |
| Nausea | Gastrointestinal disorders | Non-systematic Assessment |
|
Not provided
Not provided